Melane Sampson, Author at BioTuesdays

Developments

Adaptimmune reports changes to BOD and leadership team

Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository...

November 17, 2025

Developments

Zynex announces a series of strategic initiatives

Zynex (NASDAQ: ZYXI) has announced the engagement of financial advisory firm Province LLC, the appointment of Paul Aronzon to its board of directors, and the formation of a special committee. Mr. Paul Aronzon brings...

November 14, 2025

Developments

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025...

November 13, 2025

Developments

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating...

November 13, 2025

Developments

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...

November 12, 2025

Developments

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...

November 11, 2025

Executive Moves

Cibus elects Craig Wichner to BOD

Cibus (NASDAQ: CBUS) has announced the election of Craig Wichner to its Board of Directors (BOD) and the board’s strategy committee. “Craig brings an exceptional combination of financial acumen, strategic discipline...

November 11, 2025

Feature

Experity placing human connection at the center of AI-driven urgent care

Closely held Experity Health is shaping the future of healthcare by embedding AI into urgent care hubs across the U.S. to improve patient access, speed clinical visits, and elevate care quality.

November 11, 2025

Developments

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Closely held PharmaJet has announced that it has signed a distribution agreement with ATR, an affiliate to closely held EVA Pharma. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes...

November 6, 2025

Developments

Advicenne submits registration application to FDA for Sibnayal in dRTA

Advicenne (Euronext Growth Paris: FR0013296746—ALDVI) has announced the submission of a registration application to the FDA for Sibnayal—a fixed-dose combination of potassium citrate and potassium bicarbonate—for the...

November 5, 2025

Author - Melane Sampson

Adaptimmune reports changes to BOD and leadership team

Zynex announces a series of strategic initiatives

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Cibus elects Craig Wichner to BOD

Experity placing human connection at the center of AI-driven urgent care

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Advicenne submits registration application to FDA for Sibnayal in dRTA

Subscribe